image
Healthcare - Biotechnology - NASDAQ - US
$ 3.01
2.5 %
$ 9.03 M
Market Cap
3.3
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one KPRX stock under the worst case scenario is HIDDEN Compared to the current market price of 3.01 USD, Kiora Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one KPRX stock under the base case scenario is HIDDEN Compared to the current market price of 3.01 USD, Kiora Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one KPRX stock under the best case scenario is HIDDEN Compared to the current market price of 3.01 USD, Kiora Pharmaceuticals, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart KPRX

image
$4.2$4.2$4.0$4.0$3.8$3.8$3.6$3.6$3.4$3.4$3.2$3.2$3.0$3.0$2.8$2.8$2.6$2.6Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
16 M REVENUE
0.00%
4.51 M OPERATING INCOME
135.83%
3.59 M NET INCOME
128.73%
8.56 M OPERATING CASH FLOW
189.56%
-22.7 M INVESTING CASH FLOW
0.00%
15.5 M FINANCING CASH FLOW
159.77%
0 REVENUE
0.00%
-2.56 M OPERATING INCOME
28.80%
-4.22 M NET INCOME
-23.74%
-2.25 M OPERATING CASH FLOW
-244.81%
483 K INVESTING CASH FLOW
125.13%
0 FINANCING CASH FLOW
0.00%
Balance Sheet Kiora Pharmaceuticals, Inc.
image
Current Assets 29.7 M
Cash & Short-Term Investments 26.8 M
Receivables 871 K
Other Current Assets 2.04 M
Non-Current Assets 6.78 M
Long-Term Investments 0
PP&E 62.4 K
Other Non-Current Assets 6.72 M
73.43 %5.60 %18.41 %Total Assets$36.5m
Current Liabilities 6.01 M
Accounts Payable 416 K
Short-Term Debt 23.4 K
Other Current Liabilities 5.57 M
Non-Current Liabilities 4.72 M
Long-Term Debt 33.8 K
Other Non-Current Liabilities 4.68 M
3.88 %51.93 %43.66 %Total Liabilities$10.7m
EFFICIENCY
Earnings Waterfall Kiora Pharmaceuticals, Inc.
image
Revenue 16 M
Cost Of Revenue 0
Gross Profit 16 M
Operating Expenses 11.5 M
Operating Income 4.51 M
Other Expenses 916 K
Net Income 3.59 M
18m18m16m16m14m14m12m12m10m10m8m8m6m6m4m4m2m2m0016m016m(11m)5m(916k)4mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
28.15% OPERATING MARGIN
28.15%
22.44% NET MARGIN
22.44%
13.95% ROE
13.95%
9.85% ROA
9.85%
9.39% ROIC
9.39%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Kiora Pharmaceuticals, Inc.
image
10m10m8m8m6m6m4m4m2m2m00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 3.59 M
Depreciation & Amortization 19.2 K
Capital Expenditures -6.26 K
Stock-Based Compensation 657 K
Change in Working Capital 3.67 M
Others 3.32 M
Free Cash Flow 8.55 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Kiora Pharmaceuticals, Inc.
image
KPRX has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 9
6. Ownership
Insider Ownership Kiora Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
46.4 K USD 5
6-9 MONTHS
48.8 K USD 4
9-12 MONTHS
7. News
Kiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare Conference Ecinitas, California--(Newsfile Corp. - April 4, 2025) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company's online presentation at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10th, 2025, at 2:15 pm EDT. President & CEO, Brian M. newsfilecorp.com - 4 weeks ago
Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027 Encinitas, California--(Newsfile Corp. - March 25, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced its 2024 financial results and provided an update on its pipeline of therapeutics for the treatment of retinal diseases. Key fourth quarter and 2025 year-to-date corporate highlights include: Received approval to initiate KLARITY, a Phase 2 trial of KIO-104 for the treatment retinal inflammation. newsfilecorp.com - 1 month ago
Kiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of Proliferative Vitreoretinopathy at the ARVO 2025 Annual Meeting Encinitas, California--(Newsfile Corp. - March 12, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced their abstract of a preclinical study of KIO-104 in a proliferative vitreoretinopathy (PVR) model was accepted for poster presentation at the Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, UT, May 4-8, 2025. The findings support KIO-104 as a promising therapeutic candidate for both the prevention and treatment of PVR. newsfilecorp.com - 1 month ago
Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104 Encinitas, California--(Newsfile Corp. - February 13, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the U.S. Patent and Trademark Office has issued a composition-of-matter patent (US-12209073-B2) on a specific crystalline form, or polymorph, of KIO-104. KIO-104 is a novel, non-steroidal anti-inflammatory, small molecule inhibitor of dihydroorotate dehydrogenase (DHODH). newsfilecorp.com - 2 months ago
Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema Encinitas, California--(Newsfile Corp. - February 11, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it received regulatory approval to initiate KLARITY, a Phase 2 clinical trial to investigate KIO-104 in patients with retinal macular edema, a condition where build-up of fluid behind part of the retina can be associated with adverse vision changes. KIO-104 is a potent, locally delivered small molecule being developed as an alternative to steroids or systemic anti-inflammatory drugs, both of which have known shortcomings. newsfilecorp.com - 2 months ago
Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies Encinitas, California--(Newsfile Corp. - November 8, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced third quarter 2024 financial results and provided an update on its pipeline of therapeutics for the treatment of retinal diseases. Key third quarter and recent corporate highlights include: Investigational new drug application approval to initiate ABACUS-2, the Phase 2 study of KIO-301, a novel molecular photoswitch, for the treatment of retinitis pigmentosa. newsfilecorp.com - 5 months ago
Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa Encinitas, California--(Newsfile Corp. - October 29, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it received regulatory approval to initiate a Phase 2 clinical trial to investigate KIO-301 for vision restoration in patients with retinitis pigmentosa. The ABACUS-2 trial will be a 36 patient, multi-center, double-masked, randomized, controlled, multiple dose study enrolling patients with ultra-low vision or no light perception regardless of their underlying gene mutation associated with retinitis pigmentosa. newsfilecorp.com - 6 months ago
Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences Encinitas, California--(Newsfile Corp. - September 25, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), will participate in the following investor conferences. The presentations will be accessible live and on-demand for 90 days from our IR homepage (ir.kiorapharma.com). newsfilecorp.com - 7 months ago
Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies Encinitas, California--(Newsfile Corp. - August 9, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announces second quarter 2024 financial results and provides an update on its pipeline of therapeutics for the treatment of retinal diseases. During the quarter, Kiora finalized the trial design for the Phase 2 study (ABACUS-2) of KIO-301, a novel molecular photoswitch, for the treatment of retinitis pigmentosa through our partnership with Théa Open Innovation (TOI). newsfilecorp.com - 8 months ago
Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences Encinitas, California--(Newsfile Corp. - August 6, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), will participate in two upcoming conferences that will be available to investors by live webcast. On Tuesday August 13th, 2024 at 3:00 pm Eastern Time, Kiora's President and CEO, Brian Strem, Ph.D. newsfilecorp.com - 8 months ago
Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies Encinitas, California--(Newsfile Corp. - July 30, 2024) - Kiora Pharmaceuticals (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it has received Orphan Medicinal Product Designation from the European Medicines Agency (EMA) for the treatment of a group of inherited retinal diseases (IRDs) that include retinitis pigmentosa (RP), choroideremia and more. The broad designation covers KIO-301, a small molecule photoswitch, for the treatment of non-syndromic rod-dominant retinal dystrophies. newsfilecorp.com - 9 months ago
Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation Encinitas, California--(Newsfile Corp. - July 10, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), today announced that Eric Daniels, M.D., Chief Development Officer, will present at the Jones Trading Healthcare Seaside Summit on Monday, July 15 at 6:15 pm Eastern Time (3:15 PM Pacific Time). newsfilecorp.com - 9 months ago
8. Profile Summary

Kiora Pharmaceuticals, Inc. KPRX

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 9.03 M
Dividend Yield 0.00%
Description Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.
Contact 1371 East 2100 South, Salt Lake City, UT, 84105 https://www.kiorapharma.com
IPO Date Feb. 13, 2015
Employees 12
Officers Ms. Melissa Tosca CPA Chief Financial Officer Dr. Eric J. Daniels M.B.A., M.D. Chief Development Officer Dr. Brian M. Strem Ph.D. President, Chief Executive Officer & Director Dr. Stefan Sperl Ph.D. Executive Vice President of CMC & Operations